Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 33  |  Issue : 2  |  Page : 574-580

Topical bromfenac vs focal laser photocoagulation in treatment of focal diabetic macular edema

1 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Menouf Ophthalmology Hospital, El-Gaish Street, Menouf City, Menoufia, Egypt

Correspondence Address:
Eman A Hossam Eldin
Menouf Ophthalmology Hospital, El-Gaish Street, Menouf City, Menoufia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mmj.mmj_223_19

Rights and Permissions

Objective The aim was to evaluate the safety and efficacy of topical bromfenac in comparison with focal laser photocoagulation in treatment of focal diabetic macular edema (DME). Background DME, a serious eye condition caused primarily by hyperglycemia, is the major cause of visual loss in the working population of developed countries. Patients and methods A total of 30 eyes from 30 diabetic patients with previously untreated focal DME were enrolled in this prospective randomized controlled study from October 2017 to October 2018. Patients with central macular thickness (CMT) less than 350 μm were included. Patients were divided into two equal groups, each of 15 eyes. Group 1 patients received focal laser as needed and group 2 patients received topical bromfenac eye drops twice daily for 6 months. Best-corrected visual acuity and CMT were measured initially and at 1, 3, and 6 months of follow-up. Results After 6 months, best-corrected visual acuity was stabilized as baseline in 60 and 53.3% of group 1 and group 2 patients, respectively. After 6 months, the mean baseline CMT was significantly reduced from 290.5 ± 10.1 to 266.4 ± 8.6 μm in group 1 (P < 0.001) and from 286.9 ± 10.59 to 265 ± 14.14 μm in group 2 (P < 0.001). Conclusion Topical bromfenac showed good results close to that of focal laser on stabilization of vision and reduction of CMT in patients of focal DME with favorable safety and tolerability. Topical bromfenac twice daily for 6 months may play an effective role in treatment of early focal DME.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal